PetIQ Inc (NASDAQ:PETQ) has been assigned an average recommendation of “Buy” from the nine research firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $40.71.
A number of research firms recently issued reports on PETQ. BidaskClub downgraded shares of PetIQ from a “strong-buy” rating to a “buy” rating in a research report on Saturday, March 9th. Zacks Investment Research downgraded shares of PetIQ from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 5th. ValuEngine downgraded shares of PetIQ from a “buy” rating to a “hold” rating in a research report on Saturday, March 9th. Guggenheim began coverage on shares of PetIQ in a research report on Thursday, May 23rd. They set a “buy” rating and a $35.00 target price for the company. Finally, Raymond James dropped their target price on shares of PetIQ from $42.00 to $39.00 and set an “outperform” rating for the company in a research report on Monday, March 4th.
Shares of NASDAQ PETQ traded down $0.37 on Friday, reaching $30.12. 25,628 shares of the company traded hands, compared to its average volume of 341,037. PetIQ has a fifty-two week low of $21.29 and a fifty-two week high of $43.93. The firm’s 50 day moving average is $28.79. The company has a quick ratio of 1.51, a current ratio of 2.89 and a debt-to-equity ratio of 0.38. The company has a market capitalization of $859.82 million, a PE ratio of 24.17, a PEG ratio of 1.54 and a beta of 1.88.
PetIQ (NASDAQ:PETQ) last posted its quarterly earnings data on Wednesday, May 8th. The company reported $0.27 EPS for the quarter, beating the Zacks’ consensus estimate of $0.08 by $0.19. The company had revenue of $148.44 million during the quarter, compared to the consensus estimate of $139.03 million. PetIQ had a net margin of 0.51% and a return on equity of 9.47%. As a group, analysts anticipate that PetIQ will post 0.8 earnings per share for the current year.
In related news, Director James Nathan Clarke purchased 31,031 shares of the firm’s stock in a transaction on Wednesday, May 15th. The stock was purchased at an average price of $28.12 per share, for a total transaction of $872,591.72. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Will Santana sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $27.46, for a total value of $549,200.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 120,291 shares of company stock valued at $3,522,291. 23.79% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Manchester Capital Management LLC purchased a new position in PetIQ in the 1st quarter worth approximately $30,000. Bank of Montreal Can boosted its holdings in PetIQ by 2,007.8% in the 4th quarter. Bank of Montreal Can now owns 1,623 shares of the company’s stock worth $38,000 after acquiring an additional 1,546 shares during the period. Citigroup Inc. boosted its holdings in PetIQ by 43.5% in the 4th quarter. Citigroup Inc. now owns 1,827 shares of the company’s stock worth $43,000 after acquiring an additional 554 shares during the period. FNY Investment Advisers LLC purchased a new position in shares of PetIQ during the 1st quarter valued at approximately $56,000. Finally, Legal & General Group Plc boosted its stake in shares of PetIQ by 42.6% during the 4th quarter. Legal & General Group Plc now owns 2,451 shares of the company’s stock valued at $58,000 after buying an additional 732 shares during the last quarter. Hedge funds and other institutional investors own 91.87% of the company’s stock.
PetIQ, Inc operates as a pet health and wellness company. It operates through two segments, Products and Services. It manufactures and distributes veterinarian services and veterinarian-grade pet products, including prescription (Rx) medications, over-the-counter (OTC) flea and tick preventatives, and health and wellness products for dogs and cats.
Featured Article: How can investors find ex-dividend dates?
Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.